Article info

Original research
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Authors

  • Manu Prasad The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Jonathan Zorea The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Sankar Jagadeeshan The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Avital B Shnerb The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Sooraj Mathukkada The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Jebrane Bouaoud Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, FranceUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France PubMed articlesGoogle scholar articles
  • Lucas Michon Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France PubMed articlesGoogle scholar articles
  • Ofra Novoplansky The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Mai Badarni The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Limor Cohen The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Ksenia M Yegodayev The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Sapir Tzadok The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Barak Rotblat Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Libor Brezina The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Andreas Mock Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, GermanyDivision of Translational Medical Oncology, NCT Heidelberg, German Cancer Research Centre (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Andy Karabajakian Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, FranceUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, FranceDepartment of Medical Oncology, Centre Léon Bérard, Lyon 69373, France PubMed articlesGoogle scholar articles
  • Jérôme Fayette Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, FranceUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, FranceDepartment of Medical Oncology, Centre Léon Bérard, Lyon 69373, France PubMed articlesGoogle scholar articles
  • Idan Cohen The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Tomer Cooks The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Irit Allon Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, IsraelInstitute of Pathology, Barzilai University Medical Center, Ashkelon, Israel PubMed articlesGoogle scholar articles
  • Orr Dimitstein Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, IsraelDepartment of Otolaryngology-Head & Neck Surgery, Soroka University Medical Center, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Benzion Joshua Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, IsraelDepartment of Otorhinolaryngology and Head & Neck Surgery, Barzilai Medical Center, Ashkelon, Israel PubMed articlesGoogle scholar articles
  • Dexin Kong School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, China PubMed articlesGoogle scholar articles
  • Elena Voronov The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  • Maurizio Scaltriti Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA PubMed articlesGoogle scholar articles
  • Yaron Carmi Department of Pathology, Tel Aviv University, Tel Aviv, Israel PubMed articlesGoogle scholar articles
  • Cristina Conde-Lopez Division of Radiooncology-Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Jochen Hess Section Experimental and Translational Head and Neck Oncology, Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, GermanyResearch Group Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Ina Kurth Division of Radiooncology-Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Luc G T Morris Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Pierre Saintigny Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, FranceUniv Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, FranceDepartment of Medical Oncology, Centre Léon Bérard, Lyon 69373, France PubMed articlesGoogle scholar articles
  • Moshe Elkabets The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, IsraelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Moshe Elkabets; moshee{at}bgu.ac.il
View Full Text

Citation

Prasad M, Zorea J, Jagadeeshan S, et al
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Publication history

  • Accepted February 6, 2022
  • First published March 15, 2022.
Online issue publication 
March 15, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.